Lyell Immunopharma Q4 2024 Earnings Report

Lyell Immunopharma EPS Results

• Actual EPS: -$14.40
• Consensus EPS: -$4.00
• Beat/Miss: Missed by -$10.40
• One Year Ago EPS: N/A

Lyell Immunopharma Revenue Results

• Actual Revenue: $0.01 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Lyell Immunopharma Announcement Details

• Quarter: Q4 2024
• Date: 3/12/2025
• Time: Before Market Opens
• Conference Call Date: Tuesday, March 11, 2025
• Conference Call Time: 4:00PM ET

Lyell Immunopharma (NASDAQ:LYEL) is a clinical-stage biotechnology company focused on developing next-generation cell therapies for the treatment of cancer. The company uses proprietary technologies to identify and reverse the epigenetic programs that drive T cell dysfunction, with the goal of producing more potent and durable immune responses against solid tumors and hematologic malignancies. Lyell’s platform integrates advanced cell engineering, manufacturing automation and translational biomarker programs to optimize T cell fitness and persistence in patients.

The company’s therapeutic pipeline includes autologous tumor-infiltrating lymphocyte (TIL) programs targeting melanoma and other solid tumors, as well as allogeneic chimeric antigen receptor (CAR) T cell candidates directed against hematologic cancers. Lyell’s lead candidates leverage epigenetic modulators to reprogram exhausted T cells and enhance their ability to seek out and destroy cancer cells. In parallel, the company is advancing novel combinatorial approaches that pair engineered cell therapies with immune checkpoint inhibitors and other targeted agents to broaden clinical benefit.

Founded in 2017 and headquartered in South San Francisco, Lyell Immunopharma was established by a team of researchers and executives with deep expertise in immuno-oncology and cell therapy development. Since its inception, the company has secured strategic collaborations with academic institutions and biopharmaceutical partners to accelerate its discovery efforts and scale its manufacturing processes. Lyell completed its initial public offering in 2020 and continues to expand its research and clinical operations.

Lyell serves patients and healthcare providers primarily in North America and Europe, with growing plans for global clinical trials and regulatory filings. The company’s leadership team comprises seasoned biotech professionals, including experts in translational research, clinical development, regulatory affairs and manufacturing. Together, they aim to establish Lyell as a leader in engineered cell therapies that offer new hope for patients with hard-to-treat cancers.